{
    "organizations": [],
    "uuid": "70d425c253e4cb09287c24330ac0b16d409026a0",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-fennec-pharmaceuticals-receives-br/brief-fennec-pharmaceuticals-receives-breakthrough-therapy-designation-by-fda-for-pedmark-idUSASC09TQI",
    "ord_in_thread": 0,
    "title": "BRIEF-Fennec Pharmaceuticals Receives Breakthrough Therapy Designation By FDA For Pedmark™",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 27 (Reuters) - Fennec Pharmaceuticals Inc:\n* FENNEC PHARMACEUTICALS RECEIVES BREAKTHROUGH THERAPY DESIGNATION BY FDA FOR PEDMARK™\n* FENNEC PHARMACEUTICALS INC - ‍FDA GRANTED PEDMARK BREAKTHROUGH THERAPY DESIGNATION FOR PREVENTION OF CISPLATIN-RELATED OTOTOXICITY Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com)\n ",
    "published": "2018-03-27T19:44:00.000+03:00",
    "crawled": "2018-03-28T19:23:20.037+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "reuters",
        "fennec",
        "pharmaceutical",
        "inc",
        "fennec",
        "pharmaceutical",
        "receives",
        "breakthrough",
        "therapy",
        "designation",
        "fda",
        "fennec",
        "pharmaceutical",
        "inc",
        "granted",
        "pedmark",
        "breakthrough",
        "therapy",
        "designation",
        "prevention",
        "ototoxicity",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}